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Background: Readmission for patients with HF is an important outcome in clinical studies and health care policy. Using a large international trial, 
we examined variation in length of stay (LOS) across countries and its association with 30-day readmission rates.
Methods: We evaluated the relationship between country-level LOS and 30-day readmission in the ASCEND-HF trial. Patients who died prior to 
discharge from the index hospitalization or still hospitalized at 30 days were excluded. Hierarchical modeling was performed to evaluate whether 
LOS was associated with 30-day readmission rates at the country-level (or site-level for US analyses) while adjusting for patient-level risk factors. 
Results: Across 30 countries with 398 sites and 6,848 patients, mean LOS ranged from 4.9 to 14.6 days (US LOS: 6.1 days). Readmissions within 
30 days ranged from 0.0% to 25.0% (US: 17.8%). There was an inverse correlation between country-level mean LOS and 30-day readmission rates 
(r=-0.533, p=0.002). After multivariable adjustment, mean LOS, remained inversely related to the odds of all-cause and HF 30-day readmissions 
(Table). When limiting to index LOS of 15 days or less, the odds of all-cause and HF 30-day readmission remained significant.
Conclusions: Countries with longer HF LOS had significantly lower rates of readmission by 30 days. Findings were similar among sites in the US. 
These findings may have implications for policies towards preventing readmissions and design of clinical trials in acute HF.
